All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

CannPal Animal Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

CBD Substantially Improves Atopic Dermatitis Symptoms in Dogs

Lead Product(s): Cannabidiol

Therapeutic Area: Dermatology Product Name: DermaCann

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2020

Details:

The study design was a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of two similar DermaCann® formulations in dogs with dermatological skin conditions, using different sources of cannabidiol extracted from the hemp plant.